oaioai:dash.harvard.edu:1/28702415

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

Authors
Publication date
30 September 2016
Publisher
'Massachusetts Medical Society'
Doi

    Abstract

    The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity

    Similar works

    Full text

    thumbnail-image

    Harvard University - DASH

    redirect

    This paper was published in Harvard University - DASH.

    Having an issue?

    Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.